STX.L

Shield Therapeutics Plc
Shield Therapeutics - Results of 2024 Annual General Meeting
20th June 2024, 15:25
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 2805T
Shield Therapeutics PLC
20 June 2024
 

Shield Therapeutics plc

("Shield" or the "Company" or the "Group")

 

Results of 2024 Annual General Meeting

 

London, UK, 20 June 2024: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated specialty pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency (with or without anaemia), announces the voting results for each resolution set out in the Notice of Annual General Meeting 2024. The Board reports that all resolutions were passed: 1 to 10 passed as ordinary resolutions and 11 to 12 passed as special resolutions.

 

The following table shows the votes cast on each resolution:

 

 

VOTES
FOR

%

VOTES AGAINST

%

WITHHELD VOTES

Resolution 1

371,135,672

99.65%

1,321,765

0.35%

387,002

Resolution 2

367,256,140

98.70%

4,821,667

1.30%

766,632

Resolution 3

368,781,407

99.11%

3,296,400

0.89%

766,632

Resolution 4

368,781,161

99.11%

3,296,646

0.89%

766,632

Resolution 5

369,852,377

99.40%

2,225,430

0.60%

766,632

Resolution 6

369,852,377

99.39%

2,266,765

0.61%

725,297

Resolution 7

368,193,486

98.96%

3,884,321

1.04%

766,632

Resolution 8

371,077,210

99.63%

1,380,227

0.37%

387,002

Resolution 9

370,260,710

99.38%

2,293,669

0.62%

290,060

Resolution 10

368,304,167

98.90%

4,079,150

1.10%

461,122

Resolution 11

368,067,995

98.84%

4,305,730

1.16%

470,714

Resolution 12

367,071,290

98.53%

5,470,921

1.47%

302,228

 

Notes:

1.    Number of shares in issue 782,056,367.

2.    Details of the votes received on the resolutions are available on the Company's website:

https://www.shieldtherapeutics.com/corporate-documents/.

3.    Shield Therapeutics plc LEI: 213800G74QWY15FC3W71.

 

For further information please contact:

 

Shield Therapeutics plc

www.shieldtherapeutics.com

Greg Madison, CEO

Santosh Shanbhag, CFO

+44 (0) 191 511 8500

 

Nominated Adviser and Joint Broker


Peel Hunt LLP


James Steel / Patrick Birkholm

+44 (0)20 7418 8900



Joint Broker

Cavendish Ltd

Geoff Nash / George Dollemore/ Nigel Birks /Harriet Ward                                            

 

 

 

+44 (0)20 7220 0500



Financial PR & IR Advisor


Walbrook PR


Charlotte Edgar / Alice Woodings

+44 (0)20 7933 8780 or shield@walbrookpr.com



Investor Contact (US Advisor)

LifeSci Advisors, LLC

Joyce Allaire

 

 

jallaire@lifesciadvisors.com

 

About Iron Deficiency and Accrufer®/Feraccru®

Clinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anaemia (IDA) affect about 20 million people in the U.S. and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, Accrufer® has the potential to meet an important unmet medical need for both physicians and patients.

 

Accrufer®/Feraccru® (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA. Accrufer®/Feraccru® has a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about Accrufer®/Feraccru®, including the product label, can be found at: www.accrufer.com and www.feraccru.com.

 

About Shield Therapeutics plc

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anaemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc. (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies. Feraccru® is commercialised in the UK and European Union by Norgine B.V. (Norgine), which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd. for the development and commercialisation of Accrufer®/ Feraccru® in China, Hong Kong, Macau and Taiwan; with Korea Pharma Co., Ltd. for the Republic of Korea (Korea Pharma); and with KYE Pharmaceuticals Inc. for Canada. To learn more about Shield Therapeutics, see our website at www.shieldtherapeutics.com or follow us on LinkedIn and X.

 

Accrufer®/Feraccru® has patent coverage until the mid-2030s.

Accrufer®/Feraccru® are registered trademarks of Shield Therapeutics.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGZZGZVKGDGDZM]]>
TwitterFacebookLinkedIn